Redbiotec, a Swiss developer of a therapeutic vaccine for genital herpes, is planning to close a CHF 9m Series A round in 2020, CEO Christian Schaub told Mergermarket. The Zurich-based company will use the proceeds to advance its genital herpes (HSV-2) immunotherapy program into Phase I/IIa clinical studies.
Legalcommunity.ch
Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).
For further information, please visit the Group’s website www.lcpublishinggroup.com
SHARE
